Caris Life Sciences (CAI) vs Henry Schein (HSIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Henry Schein (HSIC) has outperformed Caris Life Sciences (CAI) over the past year, gaining 30.7% versus a loss of 16.5%. Henry Schein is the larger company by market cap ($9.44 billion vs $8.06 billion), about 1.2 times the size, while Caris Life Sciences is growing revenue faster (+97.0% vs +4.0%). On valuation, Henry Schein trades at a lower forward P/E (14.2x vs 77.2x for Caris Life Sciences).
Henry Schein converts more of its revenue into profit, with a net margin of 3.0% versus -8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | HSIC |
|---|---|---|
| Share price | $28.50 | $84.69 |
| Market cap | $8.06B | $9.44B |
| 1-day change | +3.64% | +0.07% |
| YTD return | +1.93% | +11.97% |
| 1-year return | -16.54% | +30.74% |
| 5-year return | — | +9.28% |
| P/E ratio (TTM) | 16.86 | 24.69 |
| Forward P/E | 77.21 | 14.15 |
| EPS (TTM) | $1.69 | $3.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $812.03M | $13.18B |
| Revenue growth (YoY) | +96.97% | +4.03% |
| Net income (latest FY) | $-68.09M | $398.00M |
| Gross margin | — | 31.14% |
| Operating margin | 5.56% | 4.95% |
| Net margin | -8.38% | 3.02% |
| 52-week high | $33.65 | $92.18 |
| 52-week low | $14.19 | $61.95 |
| Distance from 52-week high | -15.30% | -8.13% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +2.04% | +14.85% |
| Average volume | 4.94M | 1.22M |
| Shares outstanding | 282.68M | 111.45M |
| Employees | 1,846 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HSIC has outperformed CAI by 47.3 percentage points over the past year.
- Henry Schein trades at a higher earnings multiple (24.7x vs 16.9x trailing P/E).
- Henry Schein is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -8.4 cents for Caris Life Sciences.
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +4.03%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
CAI vs HSIC FAQ
Which is bigger, Caris Life Sciences or Henry Schein?
Henry Schein (HSIC) is larger, with a market capitalization of $9.44B compared with $8.06B for Caris Life Sciences (CAI).
Which stock has performed better over the past year, CAI or HSIC?
HSIC returned +30.74% over the past 12 months, compared with -16.54% for CAI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CAI or HSIC?
CAI has the lower trailing P/E at 16.9, versus 24.7 for HSIC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Caris Life Sciences and Henry Schein in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.